Clinuvel Pharmaceuticals Ltd has released a press release.
Vitiligo and Operational Update
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- Afamelanotide Assists DNA Repair Response Following UVR
- CLINUVEL extends Managing Director Employment Agreement
- afamelanotide in fair-skinned Parkinsons patients
- CLINUVEL initiates on market share buy-back program
- New case of SCENESSE efficacy in vitiligo presented at AAD
Later from Clinuvel Pharmaceuticals
- Appendix 4E and Annual Report to Shareholders 2024
- CLINUVEL delivers increases in annual revenue, profit
- Canadian New Drug Submission for SCENESSE in EPP filed
- Managing Director Presentation
- CLINUVEL prioritises three strategic programs
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals